MDS [clinicaltrials_resource:2851bd653baf31589bc89053c6abb31c]
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia [clinicaltrials:NCT00167167]clinicaltrials:NCT00176839clinicaltrials:NCT00176930clinicaltrials:NCT00303472clinicaltrials:NCT00309842clinicaltrials:NCT00321711Velcade in Myelodysplastic Syndrome - Pilot Study [clinicaltrials:NCT00440076]A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status [clinicaltrials:NCT00462761]clinicaltrials:NCT00472290clinicaltrials:NCT00493571clinicaltrials:NCT00614523Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders [clinicaltrials:NCT00636909]clinicaltrials:NCT00652626Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant [clinicaltrials:NCT00684008]Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders [clinicaltrials:NCT00687414]clinicaltrials:NCT00692926clinicaltrials:NCT00699842clinicaltrials:NCT00761449Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy [clinicaltrials:NCT00796562]clinicaltrials:NCT00814983Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) [clinicaltrials:NCT00815568]STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders [clinicaltrials:NCT00858572]Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) [clinicaltrials:NCT00863148]clinicaltrials:NCT00887068Umbilical Cord Blood Transplant for Hematological Malignancies [clinicaltrials:NCT00891592]clinicaltrials:NCT00923364Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders [clinicaltrials:NCT00973804]clinicaltrials:NCT01019317clinicaltrials:NCT01133275Non-interventional Study With Azacitidin (Vidaza®) [clinicaltrials:NCT01192945]clinicaltrials:NCT01204164clinicaltrials:NCT01241500SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) [clinicaltrials:NCT01261312]Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes [clinicaltrials:NCT01342692]Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS Subjects [clinicaltrials:NCT01362140]clinicaltrials:NCT01379274ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS [clinicaltrials:NCT01423175]A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome [clinicaltrials:NCT01497145]FLT-PET Imaging for MDS [clinicaltrials:NCT01535456]clinicaltrials:NCT01584531
condition [clinicaltrials_vocabulary:condition]
eligibility for clinicaltrials:NCT00389428 [clinicaltrials_resource:c4a463a9308c0cded03ccf3a0c5e8729]eligibility for clinicaltrials:NCT01596699 [clinicaltrials_resource:d0be1896ee837201bf4c6ca75d41e3c3]eligibility for clinicaltrials:NCT00186225 [clinicaltrials_resource:dbb2b51dec68e51c2f579fd6520ea096]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00475150 [clinicaltrials_resource:5ca10f2b6dd87406e1db2a4c248d1d41]eligibility for clinicaltrials:NCT00389428 [clinicaltrials_resource:c4a463a9308c0cded03ccf3a0c5e8729]eligibility for clinicaltrials:NCT01596699 [clinicaltrials_resource:d0be1896ee837201bf4c6ca75d41e3c3]eligibility for clinicaltrials:NCT00186225 [clinicaltrials_resource:dbb2b51dec68e51c2f579fd6520ea096]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
MDS [clinicaltrials_resource:2851bd653baf31589bc89053c6abb31c]
Bio2RDF identifier
2851bd653baf31589bc89053c6abb31c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2851bd653baf31589bc89053c6abb31c
identifier
clinicaltrials_resource:2851bd653baf31589bc89053c6abb31c
title
MDS
@en
type
label
MDS [clinicaltrials_resource:2851bd653baf31589bc89053c6abb31c]
@en